Pharma Partnering US: Emergent, EvolveImmune Deals Emerge

Key Takeaways

• No direct announcements from the Pharma Partnering US 2026 event were found in available sources.
• Emergent BioSolutions is partnering with Substipharm Biologics for the US manufacturing of a Japanese Encephalitis vaccine.
• EvolveImmune Therapeutics achieved a preclinical milestone in its oncology collaboration with AbbVie.
• PTC Therapeutics presented data supporting the continued development of votoplam for Huntington's disease.

While direct announcements from a "Pharma Partnering US 2026" event were not found, recent strategic manufacturing partnerships and collaborations emphasizing US operations have been reported. Key deals involve Emergent BioSolutions, EvolveImmune Therapeutics, and PTC Therapeutics, each marking significant advancements in their respective therapeutic areas.

Although specific details from a Pharma Partnering US 2026 event are unavailable, these deals highlight the ongoing dynamism within the US pharmaceutical landscape. Strategic partnerships and data presentations continue to drive innovation and address unmet medical needs.

Emergent BioSolutions and Substipharm Biologics Partnership

Emergent BioSolutions and Substipharm Biologics announced a strategic manufacturing partnership valued at $34.5 million. Emergent's facility in Canton, MA, which received a "No Action Indicated" status after a February 2026 FDA inspection, will manufacture the drug substance for the Japanese Encephalitis (JE) vaccine (IMOJEV®). This collaboration includes preparations for FDA submission and grants Emergent exclusive US government distribution rights upon approval. Scale-up and hiring are currently underway to support this initiative.

EvolveImmune Therapeutics and AbbVie Collaboration

EvolveImmune Therapeutics announced the nomination of a development candidate under its October 2024 oncology collaboration with AbbVie. This milestone triggers an $18 million preclinical payment to EvolveImmune. The collaboration leverages EvolveImmune's EVOLVE T cell engager platform to develop multi-specific T cell engagers targeting solid tumors. This marks the first program under the collaboration to reach candidate selection.

PTC Therapeutics and Novartis Data Presentation

PTC Therapeutics (PTCT) and Novartis presented a webcast featuring a 24-month interim analysis from the PIVOT-HD long-term extension study of votoplam for Huntington's disease. The data from this analysis supports the Novartis-initiated Phase 3 INVEST-HD trial. The companies plan to engage in discussions with the FDA regarding the next steps in the development of votoplam.

Market & Investor Implications

These partnerships and data presentations reflect ongoing investment and innovation within the US pharmaceutical sector. Manufacturing deals like the Emergent-Substipharm partnership signal a commitment to domestic production capabilities. Oncology collaborations, such as the EvolveImmune-AbbVie agreement, highlight the intense focus on novel therapeutic modalities. Data presentations from companies like PTC Therapeutics can influence investor sentiment and strategic decision-making.

What to Watch Next

• Progress of Emergent BioSolutions' JE vaccine manufacturing and regulatory submissions.
• Advancement of EvolveImmune's T cell engager program in collaboration with AbbVie.
• Outcomes from Novartis' Phase 3 INVEST-HD trial for votoplam in Huntington's disease.

Frequently Asked Questions

• What was the focus of Pharma Partnering US 2026?

  While direct announcements from the event are unavailable, recent reports highlight strategic manufacturing partnerships and oncology collaborations involving US-based companies.

• What is the significance of the Emergent BioSolutions and Substipharm Biologics partnership?

  This partnership aims to establish US-based manufacturing capabilities for a Japanese Encephalitis vaccine, potentially securing exclusive US government distribution rights for Emergent.

• What milestone did EvolveImmune Therapeutics achieve with AbbVie?

  EvolveImmune nominated a development candidate under its oncology collaboration with AbbVie, triggering an $18 million preclinical milestone payment.

• What is the current status of votoplam for Huntington's disease?

  Data from a 24-month interim analysis supports the Novartis-initiated Phase 3 INVEST-HD trial, with upcoming discussions planned with the FDA.

References

• Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States. BioSpace. https://www.biospace.com/press-releases/emergent-biosolutions-and-substipharm-biologics-announce-strategic-manufacturing-partnership-to-support-japanese-encephalitis-vaccine-in-the-united-states
• EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie. GlobeNewswire. https://www.globenewswire.com/news-release/2026/04/28/3282438/0/en/EvolveImmune-Therapeutics-Announces-Achievement-of-Preclinical-Milestone-in-Collaboration-with-AbbVie.html
• PTC Therapeutics to Report Results from PIVOT-HD Long-Term Extension Study. StockTitan. https://www.stocktitan.net/news/PTCT/ptc-therapeutics-to-report-results-from-pivot-hd-long-term-extension-cs3l44qj2jap.html

Related coverage

• Eli Lilly pipeline and deals: GLP-1, vaccines, and 2026 outlook
• FDA Flavored Vape Ban: Youth Risk and Pharma Implications